The cerebroside-sulfate activator protein (CSAct
or Saposin B) is a small water-soluble glycoprotein that
plays an essential role in the metabolism of certain glycosphingolipids,
especially sulfatide. Deficiency of CSAct in humans leads
to sulfatide accumulation and neurodegenerative disease.
CSAct activity can be measured in vitro by assay of its
ability to activate sulfatide–sulfate hydrolysis
by arylsulfatase A. CSAct has seven methionine residues
and a mass of 8,845 Da when deglycosylated. Mildly oxidized,
deglycosylated CSAct (+16 Da), separated from nonoxidized
CSAct by reversed-phase high-performance liquid chromatography
(RP-HPLC), showed significant modulation of the in vitro
activity. Because oxidation partially protected against
CNBr cleavage and could largely be reversed by treatment
with dithiothreitol, it was concluded that the major modification
was conversion of a single methionine to its sulfoxide.
High-resolution RP-HPLC separated mildly oxidized CSAct
into seven or more different components with shorter retention
times than nonoxidized CSAct. Mass spectrometry showed
these components to have identical mass (+16 Da). The shorter
retention times are consistent with increased polarity
accompanying oxidation of surface-exposed methionyl side
chains, in general accordance with the existing molecular
model. A mass-spectrometric CNBr mapping protocol allowed
identification of five of the seven possible methionine–sulfoxide
CSAct oxoforms. The most dramatic suppression of activity
occurred upon oxidation of Met61 (26% of control) with
other residues in the Q60MMMHMQ66
motif falling in the 30–50% activity range. Under
conditions of oxidative stress, accumulation of minimally
oxidized CSAct protein in vivo could perturb metabolism
of sulfatide and other glycosphingolipids. This, in turn,
could contribute to the onset and progression of neurodegenerative
disease, especially in situations where the catabolism
of these materials is marginal.